NCT00719550 - AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

June 30, 2013

Conditions

Esophagogastric Junction AdenocarcinomaGastric CancerEsophageal Cancer

Interventions

DRUG

Capecitabine

Administered at 625mg/m2 BID orally every day while on study.

DRUG

Epirubicin

Administered day 1 of each cycle at 50mg/m2 IV.

DRUG

AMG 102

Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.

DRUG

Cisplatin

Administered day 1 of each cycle at 60mg/m2 IV.

DRUG

Placebo

AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution